PhD, UCL School of Pharmacy, London, UK (2002) BEng Chemical Engineering, University of Southern Denmark, Odense, Denmark (1998)

Chemical tools and novel therapeutic agents; Cancer biomarkers; Hypoxia & tumour microenvironment; Molecular fluorescent probes; Aldehyde dehydrogenase; Aldo-keto reductases; Cytochromes P450

Lolli M, Narramore S, Fishwick CWG and Pors K. Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century. Drug Discovery Today. May 2015, doi: 10.1016/j.drudis.2015.04.010. [Epub ahead of print] Vinader V, Sadiq M, Sutherland M, Huang M, Loadman PM, Elsalem L, Shnyder SD, Cui H, Afarinkia K, Searcey M, Patterson LH and Pors K. Probing cytochrome P450-mediated activation with a truncated azinomycin analogue. MedChemComm, 2015, 6, 187 - 191 Pors K* and Moreb J*. Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? Drug Discovery Today. 2014 Dec;19(12):1953-63. *Joint corresponding authors Thomas A, Perry T, Berhane S, Oldreive C, Zlatanou A, Williams LR, Weston VJ, Stankovic T, Kearns P, Pors K*, Grand RJ*, Stewart GS*. The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53. Oncogene. 2014 Aug 18;0. doi: 10.1038/onc.2014.266. [Epub ahead of print]. *Joint corresponding authors Liu X, Hu L, Ge G, Yang B, Ning J, Sun S, Yang L, Pors K, Gu J. Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay. Proteomics. 2014 Aug;14(16):1943-51. doi: 10.1002/pmic.201400025. Epub 2014 Jul 14 Stenstedt K, Travica S, Guo J, Barragan I, Pors K, Patterson L, Edler D, Mkrtchian S, Johansson I, Ingelman-Sundberg M. CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer. Pharmacogenomics. 2013 Oct;14(13):1615-22. doi: 10.2217/pgs.13.136 Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K. Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity. J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26 Travica S*, Pors K*, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res. 2013 Jun 1;19(11):2952-61. doi: 10.1158/1078-0432.CCR-13-0238. Epub 2013 Apr 15. *Joint first authors Cosentino L, Redondo-Horcajo M, Zhao Y, Santos AR, Chowdury KF, Vinader V, Abdallah QM, Abdel-Rahman H, Fournier-Dit-Chabert J, Shnyder SD, Loadman PM, Fang WS, Díaz JF, Barasoain I, Burns PA, Pors K. Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties. J Med Chem. 2012 Dec 27;55(24):11062-6. doi: 10.1021/jm301151t. Epub 2012 Dec 7 Smith PJ, Wiltshire M, Chappell SC, Cosentino L, Burns PA, Pors K, Errington RJ. Kinetic analysis of intracellular Hoechst 33342--DNA interactions by flow cytometry: misinterpretation of side population status? Cytometry A. 2013 Jan;83(1):161-9. doi: 10.1002/cyto.a.22224. Epub 2012 Nov 7 Fournier-Dit-Chabert J, Vinader V, Santos AR, Redondo-Horcajo M, Dreneau A, Basak R, Cosentino L, Marston G, Abdel-Rahman H, Loadman PM, Shnyder SD, Díaz JF, Barasoain I, Falconer RA, Pors K. Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7693-6. doi: 10.1016/j.bmcl.2012.09.104. Epub 2012 Oct 10 Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1 Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse RT, Kiakos K, Bingham JP, Hartley JA, Patterson LH, Pors K. Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. doi: 10.1016/j.bcp.2012.02.017. Epub 2012 Mar 1 Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH. Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14 Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD. Use of the hollow fiber assay for the evaluation of DNA damaging agents. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30